{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:24:36Z","timestamp":1783401876986,"version":"3.54.6"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10147-025-02817-y","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T07:56:30Z","timestamp":1751270190000},"page":"1873-1881","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Platinum-rechallenge in epithelial ovarian cancer relapsing within 6 months after first-line treatment: a propensity score matching analysis"],"prefix":"10.1007","volume":"30","author":[{"given":"Laura","family":"Vertechy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Ergasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Chiamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Arrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilary","family":"Ruscito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena Maria","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Maria","family":"Sassu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-335X","authenticated-orcid":false,"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"2817_CR1","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I et al (2019) Epithelial ovarian cancer. The Lancet 393:1240\u20131253. https:\/\/doi.org\/10.1016\/S0140-6736(18)32552-2","journal-title":"The Lancet"},{"key":"2817_CR2","first-page":"227","volume":"12","author":"I Vergote","year":"2020","unstructured":"Vergote I, Denys H, De Greve J et al (2020) Treatment algorithm in patients with ovarian cancer. Facts Views Vis ObGyn 12:227\u2013239 (PMID: 33123697 PMCID: PMC7580261)","journal-title":"Facts Views Vis ObGyn"},{"key":"2817_CR3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","volume":"133","author":"A Davis","year":"2014","unstructured":"Davis A, Tinker AV, Friedlander M (2014) \u201cPlatinum resistant\u201d ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol 133:624\u2013631. https:\/\/doi.org\/10.1016\/j.ygyno.2014.02.038","journal-title":"Gynecol Oncol"},{"key":"2817_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2817_CR5","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s10147-021-02103-7","volume":"27","author":"H Nasu","year":"2022","unstructured":"Nasu H, Nishio S, Park J et al (2022) Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer. Int J Clin Oncol 27:790\u2013801. https:\/\/doi.org\/10.1007\/s10147-021-02103-7","journal-title":"Int J Clin Oncol"},{"key":"2817_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2018.05.020","volume":"150","author":"K Lindemann","year":"2018","unstructured":"Lindemann K, Gao B, Mapagu C et al (2018) Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecol Oncol 150:239\u2013246. https:\/\/doi.org\/10.1016\/j.ygyno.2018.05.020","journal-title":"Gynecol Oncol"},{"key":"2817_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ygyno.2017.11.008","volume":"148","author":"M Champer","year":"2018","unstructured":"Champer M, Huang Y, Hou JY et al (2018) Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence. Gynecol Oncol 148:19\u201327. https:\/\/doi.org\/10.1016\/j.ygyno.2017.11.008","journal-title":"Gynecol Oncol"},{"key":"2817_CR8","doi-asserted-by":"publisher","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","volume":"28","author":"S Pignata","year":"2017","unstructured":"Pignata S, Cecere SC, Du Bois A et al (2017) Treatment of recurrent ovarian cancer. Ann Oncol 28:viii51\u2013viii6. https:\/\/doi.org\/10.1093\/annonc\/mdx441","journal-title":"Ann Oncol"},{"key":"2817_CR9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/annonc\/mdw663","volume":"28","author":"MK Wilson","year":"2017","unstructured":"Wilson MK, Pujade-Lauraine E, Aoki D et al (2017) Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol 28:727\u2013732. https:\/\/doi.org\/10.1093\/annonc\/mdw663","journal-title":"Ann Oncol"},{"key":"2817_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.725264","volume":"11","author":"H Zheng","year":"2021","unstructured":"Zheng H, Shu T, Zhu S et al (2021) Construction and validation of a platinum sensitivity predictive model with multiple genomic variations for epithelial ovarian cancer. Front Oncol 11:725264. https:\/\/doi.org\/10.3389\/fonc.2021.725264","journal-title":"Front Oncol"},{"key":"2817_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.semcancer.2021.08.011","volume":"77","author":"C Marchetti","year":"2021","unstructured":"Marchetti C, De Felice F, Romito A et al (2021) Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. Semin Cancer Biol 77:144\u2013166. https:\/\/doi.org\/10.1016\/j.semcancer.2021.08.011","journal-title":"Semin Cancer Biol"},{"key":"2817_CR12","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C et al (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol Off J Am Soc Clin Oncol 30:2654\u20132663. https:\/\/doi.org\/10.1200\/JCO.2011.39.8545","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2817_CR13","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/ijgc-2019-000308","volume":"29","author":"N Colombo","year":"2019","unstructured":"Colombo N, Sessa C, du Bois A et al (2019) ESMO\u2013ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer 29:728\u2013760. https:\/\/doi.org\/10.1136\/ijgc-2019-000308","journal-title":"Int J Gynecol Cancer"},{"issue":"139","key":"2817_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejca.2020.08.021","volume":"1990","author":"A Tjokrowidjaja","year":"2020","unstructured":"Tjokrowidjaja A, Lee CK, Friedlander M et al (2020) Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. Eur J Cancer Oxf Engl 1990(139):59\u201367. https:\/\/doi.org\/10.1016\/j.ejca.2020.08.021","journal-title":"Eur J Cancer Oxf Engl"},{"key":"2817_CR15","first-page":"229","volume":"1","author":"AE Green","year":"2006","unstructured":"Green AE, Rose PG (2006) Pegylated liposomal doxorubicin in ovarian cancer. Int J Nanomed 1:229\u2013239","journal-title":"Int J Nanomed"},{"key":"2817_CR16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrclinonc.2010.120","volume":"7","author":"RD Baird","year":"2010","unstructured":"Baird RD, Tan DSP, Kaye SB (2010) Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol 7:575\u2013582. https:\/\/doi.org\/10.1038\/nrclinonc.2010.120","journal-title":"Nat Rev Clin Oncol"},{"key":"2817_CR17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ygyno.2019.09.026","volume":"155","author":"T Berg","year":"2019","unstructured":"Berg T, N\u00f8ttrup TJ, Roed H (2019) Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis. Gynecol Oncol 155:530\u2013537. https:\/\/doi.org\/10.1016\/j.ygyno.2019.09.026","journal-title":"Gynecol Oncol"},{"key":"2817_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1634\/theoncologist.9-1-33","volume":"9","author":"DK Armstrong","year":"2004","unstructured":"Armstrong DK (2004) Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. Oncologist 9:33\u201342. https:\/\/doi.org\/10.1634\/theoncologist.9-1-33","journal-title":"Oncologist"},{"key":"2817_CR19","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol 32:1302\u20131308. https:\/\/doi.org\/10.1200\/JCO.2013.51.4489","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2817_CR20","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch DG, Orlando M, Goss T et al (2007) Secord, randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol Off J Am Soc Clin Oncol. 25:2811\u20132818. https:\/\/doi.org\/10.1200\/JCO.2006.09.6735","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"2817_CR21","unstructured":"IBM Corp. Released 2022. IBM SPSS Statistics for Machintosh, Version 29.0. Armonk, NY: IBM Corp, (n.d.)"},{"key":"2817_CR22","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA et al (2011) Gynecologic Oncology Group, Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473\u20132483. https:\/\/doi.org\/10.1056\/NEJMoa1104390","journal-title":"N Engl J Med"},{"key":"2817_CR23","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/bjc.1989.132","volume":"59","author":"G Blackledge","year":"1989","unstructured":"Blackledge G, Lawton F, Redman C et al (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59:650\u2013653. https:\/\/doi.org\/10.1038\/bjc.1989.132","journal-title":"Br J Cancer"},{"key":"2817_CR24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-j","volume":"36","author":"ME Gore","year":"1990","unstructured":"Gore ME, Fryatt I, Wiltshaw E et al (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207\u2013211. https:\/\/doi.org\/10.1016\/0090-8258(90)90174-j","journal-title":"Gynecol Oncol"},{"key":"2817_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","volume":"9","author":"M Markman","year":"1991","unstructured":"Markman M, Rothman R, Hakes T et al (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol Off J Am Soc Clin Oncol 9:389\u2013393. https:\/\/doi.org\/10.1200\/JCO.1991.9.3.389","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2817_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ygyno.2015.09.011","volume":"139","author":"KH Eng","year":"2015","unstructured":"Eng KH, Hanlon BM, Bradley WH et al (2015) Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. Gynecol Oncol 139:228\u2013235. https:\/\/doi.org\/10.1016\/j.ygyno.2015.09.011","journal-title":"Gynecol Oncol"},{"key":"2817_CR27","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","volume":"147","author":"AM Oza","year":"2017","unstructured":"Oza AM, Tinker AV, Oaknin A et al (2017) Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol 147:267\u2013275. https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.022","journal-title":"Gynecol Oncol"},{"key":"2817_CR28","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-13-3141","volume":"20","author":"SV Hato","year":"2014","unstructured":"Hato SV, Khong A, de Vries IJM et al (2014) Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics, Clin. Cancer Res. Off J Am Assoc Cancer Res 20:2831\u20132837. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3141","journal-title":"Off J Am Assoc Cancer Res"},{"key":"2817_CR29","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1172\/JCI43656","volume":"121","author":"WJ Lesterhuis","year":"2011","unstructured":"Lesterhuis WJ, Punt CJA, Hato SV et al (2011) Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 121:3100\u20133108. https:\/\/doi.org\/10.1172\/JCI43656","journal-title":"J Clin Invest"},{"key":"2817_CR30","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1172\/JCI40269","volume":"120","author":"R Ramakrishnan","year":"2010","unstructured":"Ramakrishnan R, Assudani D, Nagaraj S et al (2010) Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 120:1111\u20131124. https:\/\/doi.org\/10.1172\/JCI40269","journal-title":"J Clin Invest"},{"key":"2817_CR31","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, Angelergues A, Konecny GE et al (2023) Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N Eng J. Med 389:2162\u20132174. https:\/\/doi.org\/10.1056\/NEJMoa2309169","journal-title":"N Eng J. Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02817-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02817-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02817-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T14:17:01Z","timestamp":1756390621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02817-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2817"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02817-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}